The report will be delivered in 2-3 business days.

Breast Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change

Starting Price : $ 4000.00 $3200.00 | Pages : 150 | Published : October 2020 | SKU CODE : 7723 | Format :


The breast cancer monoclonal antibodies (mAbs) market consists of sales of monoclonal antibodies by entities (organizations, sole traders and partnerships) that produce breast cancer monoclonal antibodies used as therapy for breast cancer either as monotherapy or combination therapy. The revenue generated includes the sales of naked mAbs and conjugated mAbs. The companies engaged in the breast cancer monoclonal antibodies market are primarily focused on the research, development, and production of monoclonal antibodies that are used in early-stage and advanced breast cancer, ductal carcinoma in-situ, triple-negative breast cancer, inflammatory breast cancer, and others.

The global breast cancer monoclonal antibodies market is expected to decline from $13.57 billion in 2019 to $12.60 billion in 2020 at a compound annual growth rate (CAGR) of -7.10%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $16.45 billion in 2023 at a CAGR of 9.29%.

Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibodies market’s growth. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women currently being treated and women who have completed the treatment. According to the World Health Organization (WHO), 627,000 people died of breast cancer in 2018, which is about 15% of all women cancer deaths. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibodies market.

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to impact the revenues of breast cancer monoclonal antibodies manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anti-cancer properties. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes, affecting the sales of oncology drugs. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. In 2018, the National Institute of Cancer indicated the promising results of vaccines in HER2-positive cancer including breast, ovarian, lung, colorectal, and gastroesophageal cancers, wherein they have used patients’ immune cells to treat their HER2-positive cancers by genetically modifying them to customize personalized vaccine. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibodies market.

Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. In February 2019, the FDA approved the combination of a mAb trastuzumab with hyaluronidase-oysk for SC administration in HER2-positive early breast cancer wherein hyaluronidase is an enzyme that helps the body to use trastuzumab. In 2020, The American Society of Clinical Oncology published the success of combination therapy of a targeted monoclonal antibody atezolizumab with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer. It resulted in the progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to raise the focus on these therapies in the breast cancer monoclonal antibodies market.

In March 2019, AstraZeneca, a UK-based global biopharmaceutical company that discovers, develops and commercializes prescription drugs in therapy areas such as oncology, cardiovascular, renal & metabolism and respiratory, entered into a collaboration with Daiichi Sankyo Company, Limited with an upfront payment of $1.35 billion. The collaboration agreement is about the global development and commercialization of trastuzumab deruxtecan (DS-8201), which is an exclusive antibody-drug conjugate (ADC) and potential new targeted cancer therapy. Except in Japan (exclusive rights for Daiichi Sankyo), the companies will jointly develop and commercialize trastuzumab deruxtecan. Daiichi Sankyo Company Limited is a Japan-based global pharmaceutical company that creates innovative new and generic medicines and new methods of drug discovery and delivery.

The major players covered in the global breast cancer monoclonal antibodies market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Array BioPharma, Celldex Therapeutics, Celltrion, Roche, Immunomedics, MacroGenics, Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceuticals, Puma Biotechnology, Seattle Genetics, AstraZeneca, Eddingpharm, Eisai, Galena Biopharma, ImmunoGen.

The countries covered in the global breast cancer monoclonal antibodies market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The regions covered in the global breast cancer monoclonal antibodies market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global breast cancer monoclonal antibodies market is segmented - 1) By Product: Naked Mabs, Conjugated Mabs. 2) By End-User: Hospitals, Retail Pharmacies.

    1. Executive Summary

    2. Breast Cancer Monoclonal Antibodies (mAbs) Market Characteristics

    3. Breast Cancer Monoclonal Antibodies (mAbs) Market Size And Growth

    3.1. Global Breast Cancer Monoclonal Antibodies (mAbs) Historic Market, 2015 - 2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Breast Cancer Monoclonal Antibodies (mAbs) Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Breast Cancer Monoclonal Antibodies (mAbs) Market Segmentation

    4.1. Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Naked Mabs

    Conjugated Mabs

    4.2. Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Hospitals

    Retail Pharmacies

    5. Breast Cancer Monoclonal Antibodies (mAbs) Market Regional And Country Analysis

    5.1. Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Breast Cancer Monoclonal Antibodies (mAbs) Market

    6.1. Asia-Pacific Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    6.2. Asia-Pacific Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Breast Cancer Monoclonal Antibodies (mAbs) Market

    7.1. China Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    7.2. China Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    7.3. China Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Breast Cancer Monoclonal Antibodies (mAbs) Market

    8.1. India Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    8.2. India Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    8.3. India Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Breast Cancer Monoclonal Antibodies (mAbs) Market

    9.1. Japan Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    9.2. Japan Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9.3. Japan Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Breast Cancer Monoclonal Antibodies (mAbs) Market

    10.1. Australia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10.2. Australia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Breast Cancer Monoclonal Antibodies (mAbs) Market

    11.1. Indonesia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11.2. Indonesia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Breast Cancer Monoclonal Antibodies (mAbs) Market

    12.1. South Korea Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12.2. South Korea Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Breast Cancer Monoclonal Antibodies (mAbs) Market

    13.1. Western Europe Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    13.2. Western Europe Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13.3. Western Europe Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Breast Cancer Monoclonal Antibodies (mAbs) Market

    14.1. UK Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    14.2. UK Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14.3. UK Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Breast Cancer Monoclonal Antibodies (mAbs) Market

    15.1. Germany Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15.2. Germany Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Breast Cancer Monoclonal Antibodies (mAbs) Market

    16.4. France Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16.5. France Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Breast Cancer Monoclonal Antibodies (mAbs) Market

    17.1. Eastern Europe Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    17.2. Eastern Europe Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Breast Cancer Monoclonal Antibodies (mAbs) Market

    18.1. Russia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18.2. Russia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Breast Cancer Monoclonal Antibodies (mAbs) Market

    19.1. North America Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    19.2. North America Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19.3. North America Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Breast Cancer Monoclonal Antibodies (mAbs) Market

    20.1. USA Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    20.2. USA Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20.3. USA Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Breast Cancer Monoclonal Antibodies (mAbs) Market

    21.1. South America Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    21.2. South America Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21.3. South America Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Breast Cancer Monoclonal Antibodies (mAbs) Market

    22.1. Brazil Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22.2. Brazil Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Breast Cancer Monoclonal Antibodies (mAbs) Market

    23.1. Middle East Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    23.2. Middle East Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23.3. Middle East Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Breast Cancer Monoclonal Antibodies (mAbs) Market

    24.1. Africa Breast Cancer Monoclonal Antibodies (mAbs) Market Overview

    24.2. Africa Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24.3. Africa Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Breast Cancer Monoclonal Antibodies (mAbs) Market Competitive Landscape And Company Profiles

    25.1. Breast Cancer Monoclonal Antibodies (mAbs) Market Competitive Landscape

    25.2. Breast Cancer Monoclonal Antibodies (mAbs) Market Company Profiles

    25.2.1. Amgen

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Mylan

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Merck

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. Novartis

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. GlaxoSmithKline

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Breast Cancer Monoclonal Antibodies (mAbs) Market

    27. Breast Cancer Monoclonal Antibodies (mAbs) Market Trends And Strategies

    28. Breast Cancer Monoclonal Antibodies (mAbs) Market Future Outlook and Potential Analysis

    29. Appendix

    29.1. Abbreviations

    29.2. Currencies

    29.3. Research Inquiries

    29.4. The Business Research Company

    29.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: China, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: China, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: India, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: India, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: Japan, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: Japan, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: Australia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: Australia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: Indonesia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Indonesia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: South Korea, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: South Korea, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: Western Europe, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: Western Europe, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: UK, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: UK, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: Germany, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Germany, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 27: France, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 28: France, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 29: Eastern Europe, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 31: Russia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 32: Russia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 33: North America, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 34: North America, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 35: USA, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 36: USA, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 37: South America, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 38: South America, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 39: Brazil, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 40: Brazil, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 41: Middle East, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 42: Middle East, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 43: Africa, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 44: Africa, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 45: Amgen Financial Performance
  • Table 46: Mylan Financial Performance
  • Table 47: Merck Financial Performance
  • Table 48: Novartis Financial Performance
  • Table 49: GlaxoSmithKline Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: China, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: China, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: India, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: India, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: Japan, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: Japan, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: Australia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: Australia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: Indonesia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: South Korea, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: South Korea, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: Western Europe, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: UK, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: UK, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: Germany, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Germany, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 27: France, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 28: France, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 29: Eastern Europe, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 31: Russia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 32: Russia, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 33: North America, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 34: North America, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 35: USA, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 36: USA, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 37: South America, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 38: South America, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 39: Brazil, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 40: Brazil, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 41: Middle East, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 42: Middle East, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 43: Africa, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 44: Africa, Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 45: Amgen Financial Performance
  • Figure 46: Mylan Financial Performance
  • Figure 47: Merck Financial Performance
  • Figure 48: Novartis Financial Performance
  • Figure 49: GlaxoSmithKline Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)